Tylosin tartrate is an antibiotic of the macrolide group produced by Streptomyces fradiae, is active against most gram-positive (Staphylococus spp., Streptococcus spp., Listeria monocytogenes, Corynebacterium spp., Erysipelothrix rhusiopathiae, Clostridium spp.), Campylobacter spp., Bordetella spp., Pasteurella spp., Haemophilus spp.), bacteria, mycoplasma and chlamydia.
The bacteriostatic effect of tylosin is due to the blocking of protein synthesis in the microbial cell due to the connection with the 50S ribosomal subunit and inhibition of the activity of the translocase enzyme.
When administered orally, the veterinary product is rapidly absorbed from the gastrointestinal tract and distributed in the organs, tissues and body fluids. The highest concentration of tylosin is found in the lungs, liver and kidneys. The therapeutic concentration of the antibiotic in the body is maintained for 15-18 hours.
Tylosin tartrate is excreted from the body mainly with feces, to a lesser extent - with urine, in laying birds - with eggs.